Tofacitinib is effective as monotherapy in some patients with psoriatic arthritis following withdrawal of background methotrexate, Australian-led research shows. A 12-month sub-study of 180 patients found no clinically meaningful differences in efficacy in those taking tofacitinib 5mg twice daily as monotherapy with those taking the JAK inhibitor alongside continued methotrexate. Patients taking part in the ...
Stopping methotrexate may be feasible in PsA patients taking tofacitinib
By Emma Wilkinson
23 Nov 2020